Duchenne muscular dystrophy and dystrophin: Pathogenesis and opportunities for treatment: Third in molecular medicine review series

EMBO Reports

Volumn 5, Issue 9, 2004, Pages 872-876

  Nowak, Kristen J ^a,b   Davies, Kay E ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARGININE; CALPASTATIN; CYTOSKELETON PROTEIN; DNA FRAGMENT; DYSTROPHIN; DYSTROPHIN ASSOCIATED PROTEIN COMPLEX; GENTAMICIN; MONOCLONAL ANTIBODY; MYOSTATIN; N ACETYLLACTOSAMINE SYNTHASE; NEGAMYCIN; NITRIC OXIDE SYNTHASE; OLIGONUCLEOTIDE; PLASMID DNA; PROTEASOME; PROTEASOME INHIBITOR; UTROPHIN;

CELL POPULATION; CELL TRANSPLANTATION; CHIMERAPLASTY; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; HUMAN; INHIBITION KINETICS; MOLECULAR BIOLOGY; MUSCLE REGENERATION; MYOBLAST; NONHUMAN; NONSENSE MUTATION; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENESIS; PLASMID; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; UPREGULATION; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSPLANTATION;

DYSTROPHIN; GENE THERAPY; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; OLIGONUCLEOTIDES, ANTISENSE; PROTEASOME ENDOPEPTIDASE COMPLEX; STEM CELL TRANSPLANTATION; UP-REGULATION;

EID: 16644402070     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/sj.embor.7400221     Document Type: Review

References (51)

1. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, Van Ommen GJ, den Dunnen JT, van Deutekorn JC (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12: 907-914
2. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen G, den Dunnen JT, van Deutekom JCT (2004) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74: 83-92
3. Arakawa M et al (2003) Negamycin restores dystrophin expression in skeletal muscle of mdx mice. J Biochem 134: 751-758
4. Bachrach E, Li S, Perez AL, Schienda J, Liadaki K, Volinski J, Flint A, Chamberlain J, Kunkel LM (2004) Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proc Natl Acad Sci USA 101: 3581-3586
5. Barresi R et al (2004) LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med 10: 696-703
6. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL (2002) Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 157: 137-148
7. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104: 375-381
8. Bertoni C, Rando TA (2002) Dystrophin gene repair in mdx muscle precursor cells in vitro and in vivo mediated by RNA-DNA chimeric oligonucleotides. Hum Gene Ther 13: 707-718
9. Bertoni C, Lau C, Rando TA (2003) Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping. Hum Mol Genet 12: 1087-1099
10. Blake DJ, Weir A, Newey SE, Davies KE (2002) Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 82: 291-329
11. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana T (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature 420: 418-421
12. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, Lisanti MP (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol 163: 1663-1675
13. Burkin DJ, Wallace GO, Nicol KJ, Kaufman DJ, Kaufman SJ (2001) Enhanced expression of the α7β1 intergrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol 52: 1207-1218
14. Cerletti Metal (2003) Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther 10: 750-757
15. Chaubourt E, Voisin V, Fossier P, Baux G, Israel M, De La Porte S (2002) Muscular nitric oxide synthase (muNOS) and utrophin. J Physiol Paris 96: 43-52
16. Collins CA, Morgan JE (2003) Duchenne's muscular dystrophy: Animal models used to investigate pathogenesis and develop therapeutic strategies.Int J Exp Pathol 84: 165-172
17. Dalkilic I, Kunkel LM (2003) Muscular dystrophies: Genes to pathogenesis. Curr Opin Genet Dev 13: 231-238
18. DelloRusso C, Scott J, Hartigan-O'Connor D, Salvatori G, Barjot C, Robinson AS, Crawford RW, Brooks SV, Chamberlain JS (2002) Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl/Acad Sci USA 99: 12979-12984
19. Dudley RWR, Lu Y, Gilbert R, Matecki S, Nalbantoglu J, Petrof BJ, Karpati G (2004) Sustained improvement of muscle function on year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum Gene Ther 15: 145-156
20. Dunant P, Walter MC, Karpati G, Lochmaller H (2003) Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 27: 624-627
21. Engvall E, Wewer UM (2003) The new frontier in muscular dystrophy research: Booster genes. FASEB J 17: 1579-1584
22. Ferrer A, Foster H, Wells KE, Dickson G; Wells DJ (2004) Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins. Gene ther 11 884-893
23. Gregorevic P, Chamberlain JS (2003) Gene therapy for muscular dystrophy - a review of promising progress. Expert Opin Biol Ther 3: 803-814
24. Gregorevic P, Blankenship MJ, Allen JM, Meuse L, Oakley S, Miller D, Russell D, Chamberlain JS (2004) Systemic gene transfer to striated muscles using adeno-associated viral vectors. Nat Med (in press)
25. Grounds MD, Torrisi J (2004) Anti-TNFα (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 118: 676-682
26. Hartigan-O'Connor D, Chamberlain JS (2000) Developments in gene therapy for muscular dystrophy. Microsc Res Tech 48: 223-238
27. Hoffman EP, Dressman D (2001) Molecular pathophysiology and targeted therapeutics for muscular dystrophy. Trends Pharmacology Sci 22 465-470
28. Howard MT, Anderson CB, Fass U, Khatris S, Gesteland RF, Atkins JF, Flanigan KM (2004) Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol 55: 422-426
29. Kapsa R, Quigley A, Lynch GS, Steeper K, Kornberg AJ, Gregorevic P, Austin L, Byrne E (2001) In vivo and in vitro correction of the dystrophin gene nonsense mutation by short fragment homologous replacement. Hum Gene Ther 12: 629-642
30. Khurana TS, Davies KE (2003) Pharmacological strategies for muscular dystrophy Nat Rev Drug Discov 2: 379-390
31. Liang KW, Nishikawa M, Liu F, Sun B, Ye Q, Huang L (2004) Restoration of dystrophin expression in mdx mice by intravascular injection of naked DNA containing full-length dystrophin cDNA. Gene Ther 11 901-908
32. Liu F, Nishikawa M, Clemens PR, Huang L (2001) Transfer of full-length Dmd to the diaphragm muscular of Dmd (mdx mdx) mice through systemic administration of plasmid DNA. Mol Ther 4: 45-51
33. Lu QL, Mann CJ, Lou F, Bou-Gharlos G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9: 1009-1014
34. Moghadaszadeh B et al (2003) Compensation for dystrophin-deficiency: ADAM12 overexpression. in skeletal muscle results in increased α7 integrin, utrophin and associated glycoproteins. Hum Mol Genet 12: 2467-2479
35. Nguyen H H, Jayasinha V, Xia B, Hoyte K, Martin PT (2002) Overexpression of the cytotoxic T cell Ga/NAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci USA 99 5616-5621
36. O'Hara AJ, Howell JM, Taplin RH, Fletcher S, Lloyd F, Kakulas B, Lochmuller H, Karpati G (2001) The spread of transgene expression at the site of gene construct injection. Muscle Nerve 24: 488-495
37. Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM (1989) Conversion of mdx myofibers from dystrophin negative to positive by injection of normal myoblasts. Nature 337: 76-179
38. Peng H, Huard J (2004) Muscle-derived stem cells for musculoskeletal tissue regeneration and repair. Transpl Immunol 112: 311-319
39. Perkins KJ, Davies KE (2002) The role of utrophin in the potential therapy of Duchenne muscular dystrophy. Neuromuscul Disord S1 S78-S80
40. Romero N, Benveniste O, Payan C, Brauh S, Squiban P, Herson S, Fardeau M (2002) Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: Part II, clinical protocol. Neuromuscul Disord 12 S45-S48
41. Rybakova IN, Patel JR, Davies KE, Yurhcenco PD, Ervasti JM (2002) Utrophin binds laterally along actin filaments and can couple costameric actin with the sarcolemma when overexpressed in dystrophin-deficient muscles of mice. Mol Biol Cell 13: 1512-1521
42. Sampaolesi Metal (2003) Cell therapy of α-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangloblasts. Science 301: 487-492
43. Scott JM, Li S, Harper SQ, Welikson R, Bourque D, DelloRusso C, Hauschka SD, Chamberlain JS (2002) Viral vectors for gene transfer of micro-, mini, or full-length dystrophin. Neuromuscul Disord 12: S23-S29
44. Skuk D et al (2004) Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther 9: 475-482
45. Spencer MJ, Meligren RL (2002) Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum mol Genet 11: 2645-2655
46. Straub V, Campbell KP (1997) Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol 110: 168-175
47. + stem cells restores dystrophin in mdx mice. J Cell Biol 152: 335-348
48. van Deurtekom JC, van Ommen GJ (2003) Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet 4: 774-783
49. Wehling M, Spencer MJ, Tidball JG (2001) A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 155: 123-131
50. Wells KE, Fletcher S, Mann CJ, Wilton SD, Wells DJ (2003) Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle. FEBS Lett 552: 145-149
51. Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S, Kole R (1999) Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleatides. Neuromuscul Disord 9: 330-338